Tygh Capital Management Inc. trimmed its stake in shares of Icon Plc (NASDAQ:ICLR) by 36.1% during the 4th quarter, Holdings Channel reports. The fund owned 29,497 shares of the medical research company’s stock after selling 16,694 shares during the quarter. Tygh Capital Management Inc.’s holdings in Icon were worth $3,811,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of ICLR. Massachusetts Financial Services Co. MA lifted its holdings in Icon by 12.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,070,319 shares of the medical research company’s stock worth $164,561,000 after buying an additional 121,970 shares during the period. Bank of New York Mellon Corp lifted its holdings in Icon by 10.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 164,947 shares of the medical research company’s stock worth $21,860,000 after buying an additional 15,137 shares during the period. Atria Investments LLC lifted its holdings in Icon by 18.5% in the 3rd quarter. Atria Investments LLC now owns 6,556 shares of the medical research company’s stock worth $1,008,000 after buying an additional 1,024 shares during the period. Man Group plc lifted its holdings in Icon by 40.0% in the 3rd quarter. Man Group plc now owns 72,673 shares of the medical research company’s stock worth $11,174,000 after buying an additional 20,778 shares during the period. Finally, Blackcrane Capital LLC purchased a new stake in Icon in the 4th quarter worth approximately $19,576,000. Institutional investors and hedge funds own 88.70% of the company’s stock.
ICLR has been the subject of several research analyst reports. Zacks Investment Research cut Icon from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. Evercore ISI upgraded Icon from an “in-line” rating to an “outperform” rating in a research note on Friday, October 26th. UBS Group set a $136.00 target price on Icon and gave the company a “sell” rating in a research note on Saturday, October 27th. BidaskClub cut Icon from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 20th. Finally, Goldman Sachs Group cut Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 target price for the company. in a research note on Friday, December 14th. Two investment analysts have rated the stock with a sell rating and ten have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $153.11.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2019/02/13/tygh-capital-management-inc-sells-16694-shares-of-icon-plc-iclr.html.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: What are Bollinger Bands?
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.